BioLive Wire · AI-collected
BlossomHill Therapeutics Prices $150 Million IPO at $16 Per Share
- BlossomHill Therapeutics priced its IPO at $16 per share, raising $150 million, according to the report.
Published Aug 7Source: Investing.com ↗
NLP · 3-line summary
AI Articles & Report Summaries
Expert articles and reports as a 3-line summary + takeaway
BioLive Wire · AI-collected
Latigo Biotherapeutics Prices $345.6 Million IPO at $18 Per Share
- Latigo Biotherapeutics priced its IPO at $18 per share, raising $345.6 million, according to the report.
Published Aug 7Source: Investing.com ↗
BioLive Wire · AI-collected
Eli Lilly's Revenue Soars 48%, Driven by Demand for Its GLP-1 Drugs
- Eli Lilly's revenue soared 48%, driven by demand for its GLP-1 drugs, according to the report.
- Sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss, according to the report.
Published Aug 5Source: MarketWatch ↗
BioLive Wire · AI-collected
Bayer and Plaintiffs Seek Delay in Roundup Settlement Hearing
- Bayer and plaintiffs are seeking a delay in a hearing over a Roundup litigation settlement, according to the report.
Published Aug 5Source: Investing.com ↗
BioLive Wire · AI-collected
Gilead Sciences Stock Falls Despite HIV Drug Yeztugo Beating Q2 Expectations
- Gilead Sciences' HIV prevention drug Yeztugo beat second-quarter expectations, easing concerns over soft prescription trends, but the stock fell on Wednesday, according to the report.
- Analysts focused instead on the company's existing HIV treatments Biktarvy and Descovy, which also beat estimates, aided by pricing, inventory and seasonal dynamics.
Published Aug 5Source: Investor's Business Daily ↗
BioLive Wire · AI-collected
Amgen Hikes Sales Outlook by $1 Billion After Second-Quarter Smash
- Amgen raised its sales outlook by $1 billion after a strong second-quarter beat, according to the report.
Published Aug 5Source: Investor's Business Daily ↗
BioLive Wire · AI-collected
'No Discussions' Over AstraZeneca-Bristol Myers Deal, Senior Source Says
- A senior source told Reuters there are "no discussions" between AstraZeneca and Bristol Myers Squibb over a potential deal, quashing merger speculation first reported by the Financial Times on Sunday, according to the report.
- AstraZeneca shares rose 2.9% and Bristol Myers Squibb fell 2.6% following the denial; AstraZeneca had earlier dropped about 9% in one day, its biggest such drop since 2020, after the merger reports surfaced, per the report.
Published Aug 5Source: Yahoo Finance ↗
BioLive Wire · AI-collected
CVS Stock Slides Despite Hearty Q2 Earnings Beat on Early Warnings About 2027
- CVS shares slid despite a strong Q2 earnings beat, as the company issued early warnings about 2027, according to the report.
Published Aug 5Source: Investor's Business Daily ↗
BioLive Wire · AI-collected
Eli Lilly Raises Annual Revenue Forecast as Obesity, Diabetes Drug Demand Stays Strong
- Eli Lilly raised its annual revenue forecast as demand for its obesity and diabetes drugs remained strong, with revenue soaring 48% driven by its GLP-1 medicines, according to the report.
Published Aug 5Source: Investing.com ↗
BioLive Wire · AI-collected
Gilead Second-Quarter Sales Rise 8%, Beating Wall Street Estimates
- Gilead's second-quarter sales rose 8%, beating Wall Street estimates, according to the report.
Published Aug 4Source: Investing.com ↗
BioLive Wire · AI-collected
FTC Takes Closer Look at Cencora-Covetrus Animal Health Merger, Bloomberg Reports
- The FTC is taking a closer look at the Cencora-Covetrus animal health merger, according to a Bloomberg News report.
Published Aug 4Source: Investing.com ↗
BioLive Wire · AI-collected
Novo Nordisk's Q2 Profit Beats Forecasts, Raises Outlook
- Novo Nordisk's second-quarter profit beat forecasts and the company raised its outlook, according to the report.
Published Aug 4Source: Investing.com ↗
BioLive Wire · AI-collected
Pfizer Hikes 2026 Sales Outlook by $500 Million on Second-Quarter Beat
- Pfizer raised its 2026 sales outlook by $500 million following a second-quarter earnings beat, according to the report.
Published Aug 4Source: Investor's Business Daily ↗
BioLive Wire · AI-collected
Merck Posts Better-Than-Expected Second-Quarter Results on Keytruda Strength
- Merck reported Q2 revenue of $16.61 billion, up 5% year-over-year and above analyst estimates of $16.36 billion, and raised its 2026 revenue forecast to $66.3-$67.3 billion, according to the report.
- Keytruda sales rose 5% to $8.37 billion, beating estimates of $8.07 billion, while the company posted a quarterly loss of 13 cents per share due to a $5.7 billion charge from its Terns Pharmaceuticals acquisition, per the report.
Published Aug 4Source: Yahoo Finance ↗
BioLive Wire · AI-collected
KKR to Acquire Integer Holdings in $5.7 Billion All-Cash Deal
- Integer Holdings agreed to be acquired by an affiliate of KKR in an all-cash deal valuing the medical device maker at approximately $5.7 billion, with shareholders to receive $127 per share, according to the report.
- The offer represents a 51.8% premium to Integer Holdings' closing price before its strategic review began, and the company's board unanimously approved the transaction, per the report.
- Integer Holdings is expected to become privately held and be removed from the NYSE, according to the report.
Published Aug 4Source: Yahoo Finance ↗
BioLive Wire · AI-collected
WuXi AppTec Extends Rally to Nearly Five-Year High After H1 Earnings Beat
- WuXi AppTec shares extended their rally to near a five-year high after the company's first-half earnings beat expectations, according to the report.
Published Aug 4Source: Investing.com ↗
BioLive Wire · AI-collected
Short Seller Gotham City Research Accuses Sumitomo Pharma of Misstating Revenue
- Short seller Gotham City Research accused Sumitomo Pharma of misstating its revenue, according to the report.
Published Aug 4Source: Investing.com ↗
BioLive Wire · AI-collected
Eli Lilly to Offer Early Access to Next-Gen Obesity Drug to Some Patients
- Eli Lilly will offer early access to its next-generation obesity drug to some patients, according to the report.
Published Aug 3Source: Investing.com ↗
BioLive Wire · AI-collected
Danaher Shareholders Applaud New CEO Pick
- Danaher shareholders applauded the company's new CEO pick, according to the report.
Published Aug 3Source: Investing.com ↗
BioLive Wire · AI-collected
California's Highest Court Rules for Gilead, Says Drugmakers Don't Have 'Duty to Innovate'
- California's highest court ruled in favor of Gilead, saying drugmakers don't have a "duty to innovate," according to the report.
Published Aug 3Source: Investing.com ↗
BioLive Wire · AI-collected
AstraZeneca Shares Slump After $400bn BMS Merger Rumors
- AstraZeneca shares dropped nearly 3% at market open after a report that the company is in talks with Bristol Myers Squibb on a merger that would create a combined entity worth nearly $400 billion, according to the Financial Times, cited in the report.
- AstraZeneca has a market cap of about £182 billion ($245 billion) and BMS is worth roughly $133.4 billion; Citi analysts said a merger "would be a surprise" given AstraZeneca's pipeline momentum, per the report.
Published Aug 3Source: Yahoo Finance ↗
BioLive Wire · AI-collected
Curium Deepens Radiopharma Heft With Up to $8 Billion Deal for Lantheus
- Curium agreed to a deal worth up to $8 billion to acquire Lantheus, deepening its radiopharmaceutical business, according to the report.
Published Aug 3Source: Investing.com ↗
BioLive Wire · AI-collected
AstraZeneca Investors Baulk at $400 Billion Bristol Myers Talks
- AstraZeneca investors baulked at the company's $400 billion Bristol Myers Squibb talks, according to the report.
Published Aug 3Source: Investing.com ↗
BioLive Wire · AI-collected
Sandoz Agrees $450 Million Settlement With 43 US States Over Antitrust Claims
- Sandoz agreed to a $450 million settlement with 43 U.S. states over antitrust claims, according to the report.
Published Aug 3Source: Investing.com ↗